Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies

被引：0

作者：

Emily Alouani

Benoit Rousseau

Thierry Andre

Aurelien Marabelle

机构：

[1] Toulouse Hospital University,Digestive Medical Oncology Department, IUCT

[2] Memorial Sloan Kettering Cancer Center,Rangueil

[3] Sorbonne University,Department of Medicine, Division of Solid Tumors

[4] Department of Medical Oncology,undefined

[5] Saint-Antoine Hospital,undefined

[6] AP-HP,undefined

[7] INSERM 938,undefined

[8] SIRIC CURAMUS,undefined

[9] Université Paris Saclay,undefined

[10] Gustave Roussy,undefined

[11] Departement d’Innovation Therapeutique et d’Essais Precoces (DITEP),undefined

[12] INSERM U1015 & CIC1428,undefined

来源：

Nature Cancer | 2022年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Tumors with DNA mismatch repair or proofreading deficiencies, either at the germinal or somatic level, usually present with high tumor mutational burden and often show striking responses to checkpoint blockade immunotherapy. Ongoing translational and clinical investigations of those tumor subsets provide avenues for further improvement in patient outcomes.

引用

页码：1414 / 1417

页数：3

共 15 条

[1]

Overman MJ(2022)undefined J. Clin. Oncol. 40 3510-576

[2]

Chalabi M(2020)undefined Nat. Med. 26 566-2376

[3]

Chalabi M(2022)undefined Ann. Oncol. 33 S1389-670

[4]

Cercek A(2022)undefined N. Engl. J. Med. 386 2363-555

[5]

Diaz LA(2022)undefined Lancet Oncol. 23 659-193

[6]

Cohen R(2019)undefined JAMA Oncol. 5 551-2117

[7]

Chakrabarti S(2022)undefined J. Immunother. Cancer 10 e004485-1448

[8]

Wang Z(2022)undefined J. Immunother. Cancer 10 e004703-1675

[9]

Wang Z(2022)undefined BMC Med. 20 187-undefined

[10]

Zhang C(2022)undefined J. Immunother. 45 2110-undefined

← 1 2 →